Most Read Articles
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 5 days ago

Treatment with the DPP 1* inhibitor brensocatib prolonged time to exacerbation and reduced exacerbation rates in patients with non-cystic fibrosis bronchiectasis, according to the phase II WILLOW** study presented at ERS 2020.

Pearl Toh, 18 Jan 2020
Almost three-quarters of adverse events (AEs) related to medication errors in over-the-counter (OTC) cough and cold medications (CCMs) for paediatrics required evaluation by healthcare facility and majority of the cases were due to dosing errors, a surveillance study has found, highlighting the need for interventions to mitigate medication errors.
Pearl Toh, 06 Aug 2020
A fixed-dose triple therapy of ICS, LAMA, and LABA* is superior to dual therapies of either LAMA-LABA or ICS-LABA for controlling exacerbations in patients with moderate-to-very-severe COPD**, according to the large ETHOS*** trial.

Smoking, e-cigarette use up risk of COVID-19 in youths

Stephen Padilla
24 Aug 2020

Adolescents and young adults who use electronic cigarettes or both e-cigarettes and cigarettes are at greater risk of getting infected with the novel coronavirus disease (COVID-19), suggests a study.

“[O]ur investigation informs public health concerns that the ongoing youth e-cigarette epidemic contributes to the current COVID-19 pandemic,” the researchers said.

A total of 4,351 adolescents and young adults aged 13–24 years completed an online national survey in May 2020. Multivariable logistic regression was used to examine the associations of COVID-19–related symptoms, testing, and diagnosis with cigarettes only, e-cigarettes only, and dual use, as well as with sociodemographic factors, obesity, and complying with shelter-in-place.

Diagnosis of COVID-19 was five times (95 percent confidence interval [CI], 1.82–13.96) more likely among ever-users of e-cigarettes only, seven times (95 percent CI, 1.98–24.55) more likely among ever-dual users, and 6.8 times (95 percent CI, 2.40–19.55) more likely among past 30-day dual users. [J Adolesc Health 2020;doi:10.1016/j.jadohealth.2020.07.002]

Testing was nine times (95 percent CI, 5.43–15.47) and 2.6 times (95 percent CI, 1.33–4.87) more likely among past 30-day dual users and e-cigarette only users, respectively. In addition, past 30-day dual users were 4.7 times (95 percent CI, 3.07–7.16) more likely to develop COVID-19 symptoms.

Several mechanisms drive the associations of both dual use and e-cigarette use with COVID-19 infection. First, increased exposure to nicotine and other chemicals in e-cigarettes adversely affects lung function, and previous studies show that lung damage due to e-cigarette use is similar to combustible cigarettes. [Am J Respir Crit Care Med 2019;200:1392-1401; Curr Opin Pediatr 2020;32:378-383; Eur Respir J 2018;51:1701661; Am J Respir Crit Care Med 2018;197:492-501]

Secondly, repeated touching of one’s hands to the mouth and face, which is common among users of cigarettes and e-cigarettes, promotes the spread of COVID-19. Finally, sharing of devices is also a common practice among youth e-cigarette users. [Nicotine Tob Res 2020;doi:10.1093/ntr/ntaa059; J Adolesc Health 2020;67:46-52]

Some racial/ethnic groups, particularly African American, Hispanic, and multirace youth, were also found to be at higher risk for COVID-19, and this was supported by evidence of densely populated living conditions that make social distancing challenging, greater economic stress, and service-industry work environments where working from home is less feasible. [JAMA 2020;doi:10.1001/jama.2020.8598; J Racial Ethn Health Disparities 2020;7:398-402]

Furthermore, both obesity and underweight correlated with COVID-19 outcomes. Earlier studies have shown that obesity is a risk factor for COVID-19 and being underweight affects lung function. [Pediatr Pulmonol 2014;49:1003-1010; Tanaffos 2014;13:20-26; Arh Hig Rada Toksikol 2017;68:53-58; Sci Rep 2019;9:1-10; Morb Mortal Wkly Rep 2020;69:458-464]

“[These] findings have direct implications for healthcare providers to ask all youth and COVID-19–infected youth about cigarette and e-cigarette use history; for parents, schools, and community-based organizations to guide youth to learn more about how e-cigarettes and dual use affect the respiratory and immune systems; for the Food and Drug Administration to effectively regulate e-cigarettes during the COVID-19 pandemic; and for the development and dissemination of youth-focused COVID-19 prevention messaging to include e-cigarette and dual use,” the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 5 days ago

Treatment with the DPP 1* inhibitor brensocatib prolonged time to exacerbation and reduced exacerbation rates in patients with non-cystic fibrosis bronchiectasis, according to the phase II WILLOW** study presented at ERS 2020.

Pearl Toh, 18 Jan 2020
Almost three-quarters of adverse events (AEs) related to medication errors in over-the-counter (OTC) cough and cold medications (CCMs) for paediatrics required evaluation by healthcare facility and majority of the cases were due to dosing errors, a surveillance study has found, highlighting the need for interventions to mitigate medication errors.
Pearl Toh, 06 Aug 2020
A fixed-dose triple therapy of ICS, LAMA, and LABA* is superior to dual therapies of either LAMA-LABA or ICS-LABA for controlling exacerbations in patients with moderate-to-very-severe COPD**, according to the large ETHOS*** trial.